Cardioprotective Role of Captopril: From Basic to Applied Investigations
- PMID: 40806350
- PMCID: PMC12346263
- DOI: 10.3390/ijms26157215
Cardioprotective Role of Captopril: From Basic to Applied Investigations
Abstract
Captopril, a well-established angiotensin-converting enzyme (ACE) inhibitor, has garnered attention for its cardioprotective effects in preventing heart remodeling and maintaining cardiac function, significantly improving life quality. However, recent studies have revealed that in addition to known hemodynamic alterations, captopril exhibits significant antioxidant, anti-inflammatory, and immunomodulatory effects that may underlie its protective mechanisms. Although it appeared to be overlooked in clinical practice, in recent years, additional efforts have been made to uncover the mechanisms of all drug effects, as recent research studies predict a wide spectrum of diseases beyond the recommended indications. This review thoroughly examines the mechanisms by which captopril mediates its protective effects, bridging basic biochemical observations with applied clinical investigation, especially during ischemic reperfusion (I/R) injury, hypertension, and heart failure (HF). Evidence points to captopril as a promising agent for modulating oxidative and inflammatory pathways that are crucial for cardiovascular medicine. Directions for future research are defined to determine the molecular targets of captopril further and to optimize its clinical utility in the management of cardiovascular and possibly other diseases.
Keywords: basic studies; captopril; cardiac remodeling; clinical studies; oxidative stress.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.Cochrane Database Syst Rev. 2015 Jun 4;2015(6):CD009191. doi: 10.1002/14651858.CD009191.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2021 Dec 21;12:CD009191. doi: 10.1002/14651858.CD009191.pub4. PMID: 26041152 Free PMC article. Updated.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009191. doi: 10.1002/14651858.CD009191.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2015 Jun 04;(6):CD009191. doi: 10.1002/14651858.CD009191.pub3. PMID: 23543572 Updated.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous